Abstract:Abstract Background Therapeutic lymphangiogenesis in an orthotopic lung transplant model has been shown to improve acute allograft rejection that is mediated at least in part through hyaluronan drainage. Lymphatic vessel endothelial hyaluronan receptor (LYVE-1) expressed on the surface of lymphatic endothelial cells plays important roles in hyaluronan uptake. The impact of current immunosuppressive therapies on lung lymphatic endothelial cells is largely unknown. We tested the hypothesis that FK506, the most commonly used immunosuppressant after lung transplantation, induces lung lymphatic endothelial cell dysfunction. Methods Lung lymphatic endothelial cells were cultured in vitro and treated with FK506. Telomerase activity was measured using the TRAP assay. Protein expression of LYVE-1 and senescence markers p21 and β-galactosidase was assessed with western blotting. Matrigel tubulation assay were used to investigate the effects of FK506 on TNF-α-induced lymphangiogenesis. Dual luciferase reporter assay was used to confirm NFAT-dependent transcriptional regulation of LYVE-1. Flow cytometry was used to examine the effects of FK506 on LYVE-1 in precision-cut-lung-slices ex vivo and on hyaluronan uptake in vitro . Results In vitro , FK506 downregulated telomerase reverse transcriptase expression, resulting in decreased telomerase activity and subsequent induction of p21 expression and cell senescence. Treatment with FK506 decreased LYVE-1 mRNA and protein levels and resulted in decreased LEC HA uptake. Similar result showing reduction of LYVE-1 expression when treated with FK506 was observed ex vivo . We identified a putative NFAT binding site on the LYVE-1 promoter and cloned this region of the promoter in a luciferase-based reporter construct. We showed that this NFAT binding site regulates LYVE-1 transcription, and mutation of this binding site blunted FK506-dependent downregulation of LYVE-1 promoter-dependent transcription. Finally, FK506-treated lymphatic endothelial cells show a blunted response to TNF-α-mediated lymphangiogenesis. Conclusion FK506 alters lymphatic endothelial cell molecular characteristics and causes lymphatic endothelial cell dysfunction in vitro and ex vivo. These effects of FK506 on lymphatic endothelial cell may impair the ability of the transplanted lung to drain hyaluronan macromolecules in vivo . The implications of our findings on the long-term health of lung allografts merit more investigation.

EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITRO: I. Inhibition of Expression of Alloanticen‐Activated Suppressor Cells, As Well As Induction of Alloreactivity

Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.

Effect of FK506 on Expression of CD69 and CD25 on Human Lymphocytes

Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation

Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats

Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506

FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Effect of Tacrolimus and Cyclosporine A on Suppression of Albumin Secretion Induced by Inflammatory Cytokines in Cultured Human Hepatocytes

[Inhibitory Effects of Tacrolimus on Effector T Cells from Patients with Severe Aplastic Anemia].

The Biological Activities of a Novel Immunosuppressive Agent FK520

[Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell].

[Regulatory Function of Tacrolimus and CsA on CD4/CD8 T Lymphocyte Subgroups and Costimulators on Them in Allo-Liver Recipients].

Specific Tolerance Induction of Allo-Kb-skin Grafts by FK506 in the CD8-depleted H-2k Recipients Required Low Amounts of Kb-antigen

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

M1666 Anti-Inflammatory Effects of HMPL-004 Are Mediated by the Inhibition of Multiple Targets

FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506

Anti-CD3antibody-induced Expression Ofbothp55andp75chains Ofthehighaffinity Interleukin-2 Receptor on Humant Lymphocytes Isinhibited Bycyclosporin A

Efects of Novel Immunosuppressant FK506 on Dendritic Epidermal T Cells of Mice

Clinical Study on the Use of FK506 after Renal Transplantation

Inhibition of human lymphocyte reactivity by plasma fibronectin in vitro